Literature DB >> 10477628

A common TCR V-D-J sequence in V beta 13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis.

J Hong1, Y C Zang, M V Tejada-Simon, M Kozovska, S Li, R A Singh, D Yang, V M Rivera, J K Killian, J Z Zhang.   

Abstract

T cell responses to the immunodominant peptide (residues 83-99) of myelin basic protein are potentially associated with multiple sclerosis (MS). This study was undertaken to examine whether a common sequence motif(s) exists within the TCR complementarity-determining region (CDR)-3 of T cells recognizing the MBP83-99 peptide. Twenty MBP83-99-reactive T cell clones derived from patients with MS were analyzed for CDR3 sequences, which revealed several shared motifs. Some V beta 13.1 T cell clones derived from different patients with MS were found to contain an identical CDR3 motif, V beta 13.1-LGRAGLTY. Oligonucleotides complementary to the shared CDR3 motifs were used as specific probes to detect identical target CDR3 sequences in a large panel of T cell lines reactive to MBP83-99 and unprimed PBMC. The results revealed that, in contrast to other CDR3 motifs examined, the LGRAGLTY motif was common to T cells recognizing the MBP83-99 peptide, as evident by its expression in the majority of MBP83-99-reactive T cell lines (36/44) and PBMC specimens (15/48) obtained from randomly selected MS patients. The motif was also detected in lower expression in some PBMC specimens from healthy individuals, suggesting the presence of low precursor frequency of T cells expressing this motif in healthy individuals. This study provides new evidence indicating that the identified LGRAGLTY motif is preferentially expressed in MBP83-99-reactive T cells. The findings have important implications in monitoring and targeting MBP83-99-reactive T cells in MS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477628

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Defining the parameters necessary for T-cell recognition of ligands that vary in potency.

Authors:  Neely E Kilgore; Mandy L Ford; Carrie D Margot; Daniel S Jones; Peter Reichardt; Brian D Evavold
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 2.  Determinants of public T cell responses.

Authors:  Hanjie Li; Congting Ye; Guoli Ji; Jiahuai Han
Journal:  Cell Res       Date:  2012-01-03       Impact factor: 25.617

Review 3.  Immune pathophysiology of aplastic anemia.

Authors:  Jaroslaw P Maciejewski; Antonio Risitano; Hoon Kook; Weihua Zeng; Guibin Chen; Neal S Young
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

4.  Limited heterogeneity of T cell receptor BV usage in aplastic anemia.

Authors:  W Zeng; J P Maciejewski; G Chen; N S Young
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

Review 5.  TCR peptide therapy in human autoimmune diseases.

Authors:  A A Vandenbark; E Morgan; R Bartholomew; D Bourdette; R Whitham; D Carlo; D Gold; G Hashim; H Offner
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

Review 6.  Activation pathways that drive CD4+ T cells to break tolerance in autoimmune diseases.

Authors:  Sai Harsha Krovi; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2022-02-10       Impact factor: 10.983

Review 7.  Vaccines for multiple sclerosis: progress to date.

Authors:  Jorge Correale; Mauricio Farez; Wendy Gilmore
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 8.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

9.  Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire.

Authors:  Jennifer S Sims; Boris Grinshpun; Yaping Feng; Timothy H Ung; Justin A Neira; Jorge L Samanamud; Peter Canoll; Yufeng Shen; Peter A Sims; Jeffrey N Bruce
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-03       Impact factor: 11.205

10.  A public T cell clonotype within a heterogeneous autoreactive repertoire is dominant in driving EAE.

Authors:  Juscilene S Menezes; Peter van den Elzen; Jordan Thornes; Donald Huffman; Nathalie M Droin; Emanual Maverakis; Eli E Sercarz
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.